|
RBM9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.81520354303188E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.51749998414886E-09 |
| Normal-vs-Stage2 |
2.75839999996919E-06 |
| Normal-vs-Stage3 |
2.35599995068725E-09 |
| Normal-vs-Stage4 |
1.05149999818366E-10 |
| Stage1-vs-Stage2 |
7.150000E-01 |
| Stage1-vs-Stage3 |
2.746600E-01 |
| Stage1-vs-Stage4 |
6.162800E-03 |
| Stage2-vs-Stage3 |
6.799400E-01 |
| Stage2-vs-Stage4 |
1.054610E-01 |
| Stage3-vs-Stage4 |
1.306620E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.60620455508842E-11 |
| Normal-vs-AfricanAmerican |
6.280900E-03 |
| Normal-vs-Asian |
2.20469999999695E-05 |
| Caucasian-vs-AfricanAmerican |
5.103000E-01 |
| Caucasian-vs-Asian |
8.303400E-01 |
| AfricanAmerican-vs-Asian |
6.049800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.95309995638149E-09 |
| Normal-vs-Female |
4.66899852114011E-11 |
| Male-vs-Female |
7.625000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.36239999948273E-07 |
| Normal-vs-Age(41-60Yrs) |
3.00920000029237E-09 |
| Normal-vs-Age(61-80Yrs) |
8.55382431552698E-12 |
| Normal-vs-Age(81-100Yrs) |
3.661300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.791600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.845920E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.671600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.861800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.719600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.698000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.547900E-02 |
| Classical-VS-Follicular |
1.375580E-04 |
| Classical-VS-Other |
4.060200E-01 |
| Classical-VS-Normal |
1.9618000002275E-08 |
| Tall-VS-Follicular |
4.642000E-01 |
| Tall-VS-Other |
9.408400E-01 |
| Tall-VS-Normal |
6.74410000067738E-08 |
| Follicular-VS-Other |
6.817600E-01 |
| Follicular-VS-Normal |
6.56400489518205E-11 |
| Other-VS-Normal |
1.046060E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.64669455427725E-11 |
| Normal-vs-N1 |
1.33949999980842E-08 |
| N0-vs-N1 |
4.246400E-01 |
|
|
